Harnessing the regulatory genome to create next-generation molecular therapies.
Investors 4
Mentions in press and media 5
| Date | Title | Description |
| 16.10.2017 | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Illumina Ventures Founder Nicholas Naclerio responded to questions about its investment strategy and funding priorities in an email.
He said the fund invests in life science tools, clinical diagnostics, therapeutics, and other opportunities... |
| 18.04.2017 | Thirteen new women-led healthcare startups join Springboard’s Health Innovation Hub | “We recently began to tell our story at various Med/Biotech conferences and startup challenges,” explained Singh via email. “We have to approach it judiciously and strategically and, frankly, we need a little guidance on how to navigate our... |
| 26.01.2017 | Venrock has raised $450 million for its eighth fund — just like its seventh fund | Venrock, the 47-year-old venture firm that started as the venture arm of the Rockefeller family, has closed its eighth fund with $450 million, which longtime partner Bryan Roberts calls “not too big and not too small, but just about right” ... |
| - | Thirteen new women-led healthcare startups join Springboard’s Health Innovation Hub | A new batch of 13 women-led life science and healthcare startups have been accepted into Springboard Enterprises’ Health Innovation Hub, a year-long program for growth-stage companies preparing to expand and raise funds for new product deve... |
| - | Illumina Ventures Founder talks about investment priorities for first $230M fund (Updated) | Early stage genomics businesses are the focus of Illumina Ventures’ first fund. Launched last year as the investment arm of biotech business Illumina, the firm has raised $230 million for the first fund, according to a news release.
So far ... |
Reviews 0
